Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

T-cell Acute Lymphoblastic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Northwestern

Chicago, Illinois, 60611, United States

Location status: Recruiting

Location contact

Shira Dinner, MD

CONTACT

[email protected]

312-695-2120

About this study

The primary hypothesis is that daratumumab-hyaluronidase will effectively eliminate chemotherapy refractory and relapsed MRD in T-ALL. The secondary hypotheses include; daratumumab-hyaluronidase will improve hematologic relapse free survival (RFS),daratumumab-hyaluronidase will improve overall survival (OS), patients that achieve complete MRD response with daratumumab will have improved survival outcomes, and daratumumab-hyaluronidase will be well tolerated in T-ALL after allogenic stem cell transplant.

The primary objective of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. The secondary objectives include; evaluation of morphologic relapse free survival (RFS), evaluation of overall survival (OS), assessment of the the survival outcomes in patients that undergo allogeneic stem cell transplant after complete MRD response with daratumumab-hyaluronidase, assessment of adverse effects and tolerability of daratumumab-hyaluronidase in T-ALL, and assessment of flow cytometry based MRD status on Day 64 of treatment or upon count recovery for patients that receive chemotherapy in addition to daratumumab-hyaluronidase during Course 1A.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy.
  • Patients in hematologic CR or CRi must have persistent or recurrent MRD ≥ 10-4.
  • Institution must have received central MRD status test results confirming persistent or recurrent MRD ≥ 10-4 by flow cytometry.
  • Patient may have undergone a prior allogeneic stem cell transplant, but patient may not have Grafts Versus Host Disease (GVHD) that requires ongoing immunosuppressive therapy. Patient may receive prednisone if the dose is ≤ 10 mg per day.
  • Patient must have an ECOG performance status 0-2.
  • All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 registration to rule out pregnancy.
  • Patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and continue to 3 months after the last dose of protocol treatment. Patients must also agree to abstain from donating sperm, even if they have had a successful vasectomy, or donating eggs while on study treatment and for 3 months after the last dose of protocol treatment.
  • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
  • Patient must have adequate organ and marrow function as defined below (these labs must be obtained ≤ 7 days prior to Step 1 registration).
  • Absolute neutrophil count (ANC) ≥ 750/μL
  • Platelets ≥ 75,000/μL
  • Total or Direct bilirubin ≤ 2 mg/dL
  • AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN
  • Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with prior CNS involvement are eligible as long as they do not have active CNS involvement at time of Step 1 registration.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

Exclusion criteria

-Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

Treatment and study plan

Daratumumab / Hyaluronidase Injection

Drug

Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22

Primary outcomes

  1. Complete Remission (CR)

    Time frame: Day 29

    Requires that all of the following be present.

    • Peripheral Blood Counts
    • Neutrophil count ≥ 1,000/µL.
    • Platelet count ≥ 100,000/µL.
    • Reduced hemoglobin concentration or hematocrit has no bearing on remission status.
    • Leukemic blasts must not be present in the peripheral blood.
    • Bone Marrow Aspirate and Biopsy
    • Cellularity of bone marrow biopsy must be > 20% with maturation of all cell lines.
    • ≤ 5% T lymphoblasts by flow cytometry.
    • Extramedullary leukemia, such as CNS or soft tissue involvement, must not be present.

  2. Complete Remission (CR)

    Time frame: Day 64

    Requires that all of the following be present.

    • Peripheral Blood Counts
    • Neutrophil count ≥ 1,000/µL.
    • Platelet count ≥ 100,000/µL.
    • Reduced hemoglobin concentration or hematocrit has no bearing on remission status.
    • Leukemic blasts must not be present in the peripheral blood.
    • Bone Marrow Aspirate and Biopsy
    • Cellularity of bone marrow biopsy must be > 20% with maturation of all cell lines.
    • ≤ 5% T lymphoblasts by flow cytometry.
    • Extramedullary leukemia, such as CNS or soft tissue involvement, must not be present.

  3. Complete Response with Partial Count Recovery (CRh)

    Time frame: Day 29

    The same as for CR except with unsupported platelets > 50,000/μL, hemoglobin > 7 g/dL, and absolute neutrophil count > 500/μL.

  4. Complete Response with Partial Count Recovery (CRh)

    Time frame: Day 64

    The same as for CR except with unsupported platelets > 50,000/μL, hemoglobin > 7 g/dL, and absolute neutrophil count > 500/μL.

  5. Complete Remission incomplete (CRi)

    Time frame: Day 29

    All the same response criteria in peripheral blood and bone marrow as CR with the exception that there is incomplete platelet recovery (platelets > 75,000/uL but < 100,000/μL independent of platelet transfusions) or incomplete neutrophil count recovery > 750/uL but < 1000/μL.

  6. Complete Remission incomplete (CRi)

    Time frame: Day 64

    All the same response criteria in peripheral blood and bone marrow as CR with the exception that there is incomplete platelet recovery (platelets > 75,000/uL but < 100,000/μL independent of platelet transfusions) or incomplete neutrophil count recovery > 750/uL but < 1000/μL.

  7. Minimal Residual Disease Negativity (MRD-)

    Time frame: Day 29

    Bone marrow lymphoblast percent < 0.01% (< 10-4) by flow cytometry in a patient that fulfills count requirements for CR/CRh/CRi..

  8. Minimal Residual Disease Negativity (MRD-)

    Time frame: Day 64

    Bone marrow lymphoblast percent < 0.01% (< 10-4) by flow cytometry in a patient that fulfills count requirements for CR/CRh/CRi..

  9. Morphologic Relapse

    Time frame: Day 29

    Bone Marrow Aspirate and Biopsy

    • Presence of > 5% T lympho-blasts, not attributable to another cause (e.g., bone marrow regeneration).
    • If there are no circulating blasts and the bone marrow contains 5% to 20% blasts, then a repeat bone marrow performed ≥ 1 week later documenting more than 5% blasts is necessary to meet the criteria for relapse.

  10. MRD Relapse

    Time frame: Day 29

    • Relapse following MRD negativity is defined as bone marrow T lymphoblast percent ≥ 0.01% (10-4).

  11. Morphologic Relapse

    Time frame: Day 64

    Bone Marrow Aspirate and Biopsy

    • Presence of > 5% T lympho-blasts, not attributable to another cause (e.g., bone marrow regeneration).
    • If there are no circulating blasts and the bone marrow contains 5% to 20% blasts, then a repeat bone marrow performed ≥ 1 week later documenting more than 5% blasts is necessary to meet the criteria for relapse.

  12. MRD Relapse

    Time frame: Day 64

    • Relapse following MRD negativity is defined as bone marrow T lymphoblast percent ≥ 0.01% (10-4).

  13. Refractory

    Time frame: Day 29

    Failure to achieve MRD negativity as defined by bone marrow with CR/CRh/CRi with T lymphoblast percent ≥ 0.01% (10-4).

  14. Refractory

    Time frame: Day 64

    Failure to achieve MRD negativity as defined by bone marrow with CR/CRh/CRi with T lymphoblast percent ≥ 0.01% (10-4).

Study contacts

Contact information is provided by the study sponsor or research team.

Shira Dinner, MD

CONTACT

[email protected]

312-695-6180

Talha Badar, MD

CONTACT

[email protected]

904-953-7556

Sponsors and collaborators

Lead sponsor

Eastern Cooperative Oncology Group

Network

Collaborators

  • Janssen, LP

Registry information

Official study title

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Mar 21, 2022
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.